Benzphetamine Hcl (benzphetamine HCl)

Dosage of benzphetamine hydrochloride should be individualized according to patient response. When the drug is used as an adjunct in the short-term treatment of exogenous obesity, the manufacturer suggests an initial adult dosage of 25-50 mg once daily, preferably given in midmorning or midafternoon according to the patient's dietary habits; it may be desirable to avoid late afternoon administration in some patients. The dose or frequency of administration may be subsequently increased based on patient response and tolerability. The suggested dosage ranges from 25-50 mg 1-3 times daily. However, the least amount feasible should be prescribed or dispensed at one time to avoid the possibility of overdosage.

Benzphetamine hydrochloride is administered orally.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

*Patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to sympathomimetic amines, and glaucoma.

*Patients who are in an agitated state or who have a history of drug abuse.

*Concomitant use or use within 14 days following monoamine oxidase inhibitors.

*Concomitant use with other CNS stimulants.

*Women who are or may become pregnant.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

Adverse effects of benzphetamine have included palpitation, tachycardia, elevated blood pressure, isolated reports of cardiomyopathy and ischemic cardiac events associated with chronic use, overstimulation, restlessness, dizziness, insomnia, tremor, sweating, headache, psychotic episodes, depression following withdrawal of the drug, dryness of the mouth, unpleasant taste, nausea, diarrhea, urticaria and other allergic skin reactions, and changes in libido.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

Safety and effectiveness of benzphetamine in patients <17 years of age have not been established.

Benzphetamine may cause fetal toxicity when administered to pregnant women. Amphetamines have been shown to be teratogenic and embryotoxic in animals at dosages higher than the recommended human dosage.Benzphetamine is contraindicated in women who are or may become pregnant. If benzphetamine is administered during pregnancy or if the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus.

Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing

Manufacturer makes no special dosage recommendations.

Clinical studies of benzphetamine did not include sufficient numbers of subjects >=65 years of age to establish safety and efficacy in this population. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.